Eli Lilly hiked its revenue growth guidance by 7%, while Novo Nordisk was forced to slash its targets by ~12%. See why I'm still bullish on LLY stock.
The U.S. Food and Drug Administration approved Novo Nordisk's weight-loss pill on Monday, giving the Danish drugmaker a leg ...
Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...
TipRanks on MSN
Eli Lilly (LLY) says obesity pill helps maintain weight loss as patients switch from Zepbound
U.S. pharmaceutical company Eli Lilly & Co. (LLY) says that its new obesity pill helped patients maintain the majority of ...
Eli Lilly has shown patients maintained most of their weight loss after switching from injectable GLP-1s to its oral drug ...
Eli Lilly’s experimental weight-loss drug retatrutide led to an average weight reduction of up to 28.7%—more than 71 ...
Morning Overview on MSN
What counts as high mileage on a 6.6 Duramax?
High mileage on a 6.6 Duramax is less about a single scary number on the odometer and more about how that number lines up ...
Eli Lilly (LLY) announced on Tuesday that its Bruton tyrosine kinase inhibitor Jaypirca (pirtobrutinib) reached the main goal in a Phase 3 trial for certain newly diagnosed patients with chronic ...
Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The company still has a robust business that is delivering excellent results and ...
Shares of Eli Lilly and Co (NYSE:LLY) are sliding into the red, down 0.8% to trade at $1,066.96 at last check, amid news the pharma giant cut prices on popular weight loss drug Zepbound. The ...
Multiple Scripts: Add as many custom JavaScript snippets as you want. Organized UI: Each script is managed in its own collapsible section, keeping your configuration clean and easy to navigate. Enable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback